Global /United States /Healthcare /Drug Manufacturers - General /ONPH
chevron_leftBack
Oncology Pharma Inc. logo

Oncology Pharma Inc.

ONPH
OTCMKTS: ONPH Delayed
0.0750USD 5.5%
As of 15 June 2026, Oncology Pharma Inc. has a market cap of $2.9M USD, ranking #46261 globally and #5869 in the United States. It ranks #4101 in the Healthcare sector, and #1308 in the Drug Manufacturers - General industry.
Global Rank
46261
Country Rank
5869
Sector Rank
4101
Industry Rank
1308
Key Stats
Market Cap
$2.9MUSD
Revenue (TTM)
$10.21KUSD
EBITDA (TTM)
-$8.65KUSD
Net Income (TTM)
$186.04KUSD
EBITDA Margin
-85%
Profit Margin
2K%
PE Ratio
15.6
PS Ratio
283.9
PB Ratio
-13.2
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
George Malesek open_in_new
Employees
18
Founded
1993
Website
oncology-pharma.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
5.5% 1.6% -6.6% 1K% 3K% 71K%

News

Loading...

Markets

Exchange Ticker Price
OTC Markets
MIC: OTCM
PRIMARY
ONPH
Oncology Pharma Inc
ISIN: US68235J2015
Shares Out.:
27.388M1 Shares Float: 15.222M2
TV:
SA:
YF:
GF:
BA:
MS:
0.0750 USD
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Oncology Pharma Inc.

Oncology Pharma Inc., an oncology company, develops, manufactures, and commercializes therapeutics. The company has a collaboration and licensing agreement with Kalos Therapeutics Inc. for exploring treatment opportunities of the COVID-19 virus. The company was formerly known as SourcingLink.net Inc. and changed its name to Oncology Pharma Inc. in June 2019. Oncology Pharma Inc. was incorporated in 1993 and is based in San Francisco, California.

Similar Companies

Industry: Drug Manufacturers - General (United States)
Name
Market Cap diff.
PE
LLY
$761.68B
26M%
38.1
JNJ
$547.28B
19M%
26.4
ABBV
$360.63B
12M%
97.4
MRK
$274.03B
9M%
15.1
PFE
$149.38B
5M%
19.5
$117.58B
4M%
16.8
Industry: Drug Manufacturers - General (Global)
Name
Market Cap diff.
PE
$321.52B
256.25B CHF
11M%
19.9
AZN
$288.84B
215.59B GBP
10M%
27.6
NOVN
$274.65B
218.9B CHF
9M%
20.5
NOVO-B
$181.82B
1.18T DKK
6M%
11.5
SAN
$110.1B
95.26B EUR
4M%
19.9
GSK
$108.46B
80.96B GBP
4M%
14.6
chevron_leftBack